CARDIOVASCULAR RADIOLOGY / REVIEW PAPER
Interpretation of cardiac magnetic resonance imaging of left ventricular hypertrophy: a practical guide
1
Department of Radiology, Nihon University Hospital, Tokyo, Japan
2
Department of Radiology, Nippon Medical School, Tokyo, Japan
3
Department of Cardiology, Nihon University Hospital, Tokyo, Japan
Submission date: 2025-05-12
Final revision date: 2025-11-22
Acceptance date: 2025-12-19
Publication date: 2026-04-27
Corresponding author
Yasuo Amano
Department of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
Department of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
Pol J Radiol, 2026; 91(1): 205-215
KEYWORDS
TOPICS
ABSTRACT
The aim of this paper is to guide the interpretation of cardiac magnetic resonance imaging (MRI) of patients with left ventricular hypertrophy (LVH) through clinical examples acquired in daily practice. The clinical utility of cardiac MRI for determining the etiologies of LVH and stratifying their risks for heart failure and cardiac death is enhanced by combining clinical information, including patient’s age, family history, and noncardiac past history in patients with LVH. In this review, we report the clinical information necessary for interpreting cardiac MRI of patients with LVH. Next, the cardiac MRI sequences and their interpretation for differentiating LVH are described. Finally, we review clinical examples presenting with LVH on MRI.
REFERENCES (54)
1.
Burrage MK, Ferreira VM. Cardiovascular magnetic resonance for the differentiation left ventricular hypertrophy. Curr Heart Fail Rep 2020; 17: 192-204.
2.
Licordari R, Trimarchi G, Teresi L, Restelli D, Lofrumento F, Per- na A, et al. Cardiac magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and therapeutic management. J Clin Med 2023; 12: 3481. DOI: 10.3390/jcm12103481.
3.
Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ. Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study cardiac magnetic resonance study. J Am Heart Assoc 2015; 4: e002188. DOI: 10.1161/JAHA.115.002188.
4.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
5.
Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010; 121: 445-456.
6.
Hiestand R, Nowak A, Sokolska JM, Chan R, Ruschitzka F, Manka R, Gruner C. Clinical and CMR characteristics associated with cardiac events in patients with Fabry disease. Int J Cardiol 2023; 382: 46-51. .
7.
Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43: 2260-2264.
8.
Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 2013; 99: 932-937.
9.
Niu J, Zeng M, Wang Y, Liu J, Li H, Wang S, et al. Sensitive marker for evaluation of hypertensive heart disease: extracellular volume and myocardial strain. BMC Cardiovasc Dis 2020; 20: 292. DOI: 10.1186/s12872-020-01553-7.
10.
Kitamura M, Amano Y, Takayama M, Shibuya J, Matsuda J, Sangen H, et al. Usefulness of non-anteroseptal region left ventricular hypertrophy using cardiac magnetic resonance to predict repeat alcohol septal ablation for refractory obstructive hypertrophic cardiomyopathy. Am J Cardiol 2017; 120: 124-130.
11.
Dobner S, Bernhard B, Ninck L, Wiesler M, Bakula A, Wahl A, et al. Impact of tafimidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy. ESC Heart Fail 2024; 11: 2759-2768.
12.
Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009; 95: 1103-1107.
13.
Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, et al. SEQUOIA-HCM Investigators. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy. SEQUOIA-HCM CMR substudy. J Am Coll Cardiol 2024; 84: 1806-1817. DOI: 10.1016/j.jacc.2024.08.015. .
14.
Am Heart Association. Hypertrophic Cardiomyopathy (HCM) risk calculator for sudden cardiac death [Internet]. Available at: https://professional.heart.org....
15.
Salemi VMC, Demarchi LMMF, Cabeda EV, Wagenfuhr J, Tana- ka AC. Type III glycogen storage disease mimicking hypertro- phic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2012; 13: 197. DOI: 10.1093/ejechocard/jer231. .
16.
Hudsmith LE, Petersen SE, Francis JM, Robson MD, Watkins H, Neubauer S. Hypertrophic cardiomyopathy in Noonan syndrome closely mimics familiar hypertrophic cardiomyopathy due to sarcomeric mutations. Int J Cardiovasc Imaging 2006; 22: 493-495. .
17.
Carabello BA. The symptoms of aortic stenosis: a step closer to understanding their cause. JACC Cardiovasc Imaging 2013; 6: 147-149.
18.
Kaneko H, Suzuki S, Goto M, Arita T, Yuzawa Y, Yagi N, et al. Presentations and outcome of patients with acute decompensated heart failure admitted in the winter season. J Cardiol 2014; 64: 470-475.
19.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019; 73: 2872-2891.
20.
Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7: 204-214.
21.
Averbuch T, White JA, Fine NM. Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management, and monitoring strategies. Fron Cardiovasc Med 2023; 10: 1152568. DOI: 10.3389/fcvm.2023.1152568.
22.
Zhao H, Tan Z, Liu M, Yu P, Ma J, Li X, et al. Is there a sex difference in the prognosis of hypertrophic cardiomyopathy? A systemic review and meta-analysis. J Am Heart Assoc 2023; 12: e026270. DOI: 10.1161/JAHA.122.026270.
23.
Tadic M, Cuspidi C, Plein S, Belyavskiy E, Heinzel F, Galderisi M. Sex and heart failure with preserved ejection fraction: from pathophysiology to clinical studies. J Clin Med 2019; 8: 792. DOI: 10.3390/jcm8060792.
24.
Fumagalli C, Maurizi N, Day SM, Ashley EA, Michels M, Colan SD, et al. Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. JAMA Cardiol 2020; 5: 65-72.
25.
Yilmaz A, Gdynia HJ, Ponfick M, Rosch S, Lindner A, Ludolph AC, Sechtem U. Cardiovascular magnetic resonance imaging (CMR) reveals characteristic pattern of myocardial damage in patients with mitochondrial myopathy. Clin Res Cardiol 2012; 101: 255-261. .
26.
Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, et al. Relationship between genotype status and clinical outcome in hypertrophic cardiomyopathy. J Am Heart Assoc 2024; 13: e033565. DOI: 10.1161/JAHA.123.033565. .
27.
Amano Y, Kitamura M, Takano H, Yanagisawa F, Tachi M, Suzuki Y, et al. Cardiac MR imaging of hypertrophic cardiomyopathy: techniques, findings, and clinical relevance. Magn Reson Med Sci 2018; 17: 120-131.
28.
Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle D, Rakowski H. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 638-645. DOI: 10.1016/s0735-1097(01)01778-8.
29.
Amano Y, Aita K, Yamada F, Kitamura M, Kumita S. Distribution and clinical significance of high signal intensity of myocardium on T2-weighted images in 2 phenotypes of hypertrophic cardiomyopathy. J Comput Assist Tomogr 2015; 39: 951-955.
30.
Sozzi FB, Iacuzio L, Belmonte M, Schiavone M, Bursi F, Gher- besi E, et al. Early diagnosis of cardiomyopathies by cardiac magnetic resonance. overview of the main criteria. Monaldi Arch Chest Dis 2022; 92: 2151. DOI: 10.4081/monaldi.2022.2151.
31.
Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26: 1461-1474.
32.
Takeda M, Amano Y, Tachi M, Tani H, Mizuno K, Kumita S. MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, hypertensive heart disease. Jpn J Radiol 2013; 31: 693-700.
33.
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden cardiac death risk in patients with hypertrophic cardiomyopathy. Circulation 2014; 130: 484-495.
34.
Hiestand R, Nowak A, Sokolska JM, Chan R, Ruschnitzka F, Manka R, Gruner C. Clinical and CMR characteristics associated with cardiac events in patients with Fabry disease. Int J Cardiol 2023; 382: 46-51.
35.
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banyper- sad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015; 132: 1570-1579.
36.
Stachera M, Przybyto P, Sznajder K, Gierlotka M. Cardiac magnetic resonance in the assessment of hypertrophic cardiomyopathy phenotypes and stages − pictorial review. Pol J Radiol 2021; 86: e672-e684. DOI: 10.5114/pjr.2021.112310.
37.
Sipola P, Magga J, Husso M, Jääskelainen P, Peuhkurinen K, Kuusisto J. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. Eur Radiol 2011; 21: 1383-1389. .
38.
Pennacchini E, Musumeci MB, Fierro S, Francia P, Autore C. Distinguishing hypertension from hypertrophic cardiomyopathy as a cause of left ventricular hypertrophy. J Clin Hypertens (Greenwich) 2015; 17: 239-241. DOI: 10.1111/jch.
39.
Andersen K, Hennersdorf M, Cohnen M, Blondin D, Modder U, Poll LW. Myocardial delayed contrast enhancement in patients with arterial hypertension: initial results of cardiac MRI. Eur J Radiol 2009; 71: 75-81.
40.
Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 2021 ; 53: 135-142.
41.
Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol 2019; 74: 2333-2345.
42.
Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gib- son CM, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010; 106: 261-267.
43.
Lee H, Park JB, Yoon YE, Park EA, Kim HK, Lee W, et al. Noncontrast myocardial T1 mapping by cardiac magnetic resonance predicts outcome in patients with aortic stenosis. JACC Cardiovasc Imaging 2018; 11: 974-983.
44.
Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 2017; 19: 98. DOI: 10.1186/s12968-017-0415-x.
45.
Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 2015; 277: 388-397. .
46.
Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, et al. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Aderson-Fabry disease. J Cardiovasc Magn Reson 2016; 18: 14. DOI: 10.1186/s12968-016-0233-6.
47.
Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008; 51: 50-59.
48.
Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013; 6: 392-398. .
49.
Hayer MK, Radhakrishnan A, Price AM, Liu B, Baig S, Weston CJ, et al. Defining myocardial abnormalities across the stages of chronic kidney disease: a cardiac magnetic resonance imaging study. JACC Cardiovasc Imaging 2020; 13: 2357-2367.
50.
Arcari L, Hinojar R, Engel J, Freiwald T, Platschek S, Zainal H, et al. Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions – comparison of uremic, hypertensive, and hypertrophic cardiomyopathy. Int J Cardiol 2020; 306: 102-108.
51.
Shroff GR, Raggi P. Exploring the elusive link between subclinical fibrosis and clinical events in the end-stage renal disease: does cardiac magnetic resonance imaging hold the key? Kidney Int 2016; 90: 729-732.
52.
Kebed KY, Bos JM, Anavekar NS, Mulvagh SL, Ackerman MJ, Ommen SR. Hypertrophic cardiomyopathy, athlete’s heart, or both: a case of hypertrophic cardiomyopathy regression. Circ Cardiovasc Imaging 2015; 8: e003312. DOI: 10.1161/CIRCIMAGING.115.003312.
53.
Hamada M, Ogimoto A, Otani T, Ikeda S, Shigematsu Y. Impact of chronic cibenzoline therapy on left ventricular remodeling in patients with hypertrophic non-obstructive cardiomyopathy. Circ J 2025; 25: 921-929.
54.
Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H, et al. Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC expert panel. Am J Cardiol 2022; 180: 124-139. DOI: 10.1016/ j.amjcard.2022.06.007.
Share
RELATED ARTICLE
| ISSN: | 1899-0967 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
